Minimum Information about a Flow Cytometry Experiment
MIFlowCyt 1.0
A standard for outlining the minimum information required to report the experimental details of flow cytometry experiments
Original Article
- Lee JA et al.: MIFlowCyt: The minimum information about a flow cytometry experiment, Cytometry 73A, 926-930.
- See also the PubMed Reference
Document Status
MIFlowCyt is an ISAC Recommendation. This document has been reviewed by members of the International Society for Analytical Cytology (ISAC) and other interested parties and has been endorsed by the ISAC President and ISAC Council as an ISAC Recommendation. It is a stable document and may be used as reference material. This document has been produced by the ISAC Data Standards Task Force (ISAC DSTF) and other members of scientific community as acknowledged below.- Jamie Lee, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX USA
- Josef Spidlen, Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC Canada
- Keith Boyce, Immune Tolerance Network, Pittsburgh, PA USA
- Jennifer Cai, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX USA
- Nicholas Crosbie, Inivai Technologies, Victoria, Australia
- Mark Dalphin, Amgen Inc., Thousand Oaks, CA USA
- Jeff Furlong, Department of Immunology, University of Washington, Seattle, WA USA
- Maura Gasparetto, Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC Canada
- Elizabeth M. Goralczyk, Fox Chase Cancer Center, Philadelphia, PA USA
- Bill Hyun, Biotrue Inc., San Francisco, CA USA
- Kirstin Jansen, Department of Immunology, University of Washington, Seattle, WA USA
- Tobias Kollmann, Vaccine Evaluation Center, Child and Family Research Institute, Department of Pediatrics, University of British Columbia, Vancouver, V5Z 4H4, BC, Canada
- Megan Kong, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX USA
- Robert Leif, Newport Instruments, San Diego, CA USA
- Shannon K. McWeeney, OHSU Cancer Institute; Division of Biostatistics, Department of Public Health and Preventive Medicine; Oregon Clinical and Translational Research Institute; Oregon Health and Science University, Portland, OR, USA
- Thomas D. Moloshok, Fox Chase Cancer Center, Philadelphia, PA USA
- Wayne Moore, Herzenberg Laboratory FACS Development Group, Genetics Department, Stanford University School of Medicine, Stanford, CA 94305, USA
- Garry Nolan, Department of Microbiology and Immunology, Stanford University, Stanford, CA USA
- John Nolan, La Jolla Bioengineering Institute, La Jolla, CA USA
- Janko Nikolich-Zugich, Department of Molecular Microbiology and Immunology, Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR USA
- David Parrish, Immune Tolerance Network, Pittsburgh, PA USA
- Barclay Purcell, Cytopeia Incorporated, Seattle, WA USA
- Yu Qian, Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX USA
- Biruntha Selvaraj, Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR USA
- Clayton Smith, Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC Canada
- Olga Tchuvatkina, Fox Chase Cancer Center, Philadelphia, PA USA
- Anne Wertheimer, Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health and Science University, Portland, OR USA
- Peter Wilkinson, Centre de recherche du Centre hospitalier de l'Universitée Montré, (CHUM) - Hopital St-Luc, Montreal, QC Canada
- Christopher Wilson, Department of Immunology, University of Washington, Seattle, WA USA
- James Wood, Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA
- Robert Zigon, Beckman Coulter, Inc. 7451 Winton Drive, Indianapolis, IN USA
- ISAC Data Standards Task Force
- Richard Scheuermann, Department of Pathology and Division of Biomedical Informatics, University of Texas Southwestern Medical Center, Dallas, TX USA
- Ryan R. Brinkman, Terry Fox Laboratory, BC Cancer Research Centre, Vancouver, BC Canada
The International Society for Analytical Cytology (ISAC, http://www.isac-net.org)
The Flow Informatics and Computational Cytometry Society (http://www.ficcs.org)
The Bioinformatics Standards for Flow Cytometry Consortium (http://flowcyt.sf.net)
MIFlowCyt development has been supported by NIH grant EB005034 from the National Institute of Biomedical Imaging and Bioengineering and by the NIAID Bioinformatics Integration Support Contract AI40076 (BISC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Biomedical Imaging and Bioengineering or the National Institutes of Health. Special thanks to James Wood for chairing the ISAC adoption process.
Abstract
The fundamental tenet of scientific research is that the published results of any study have to be open to independent validation or refutation. The Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) establishes criteria for recording and reporting information about the flow cytometry experiment overview, samples, instrumentation and data analysis. It promotes consistent annotation of clinical, biological and technical issues surrounding a flow cytometry experiment by specifying the requirements for data content and by providing a structured framework for capturing information.
MIBBI
Throughout the biological and biomedical sciences prescriptive checklists specifying the key information to include when reporting experimental results are beginning to find favour with experimentalists, analysts, publishers and funders alike. In order to simplify cross-domain comparison and integration, MIFlowCyt has been developed in a coordinated manner with checklists for other high-throughput experiments that are joined within the Minimum Information for Biological and Biomedical Investigations (MIBBI) project.
MIFlowCyt download
Please download MIFlowCyt in the download section.
Alternatively the following links may be used to access the document:
- ISAC Recommendation from February 2008: http://www.isac-net.org/media/standards/miflowcyt/MIFlowCyt_080221.pdf
- Latest version from ISAC web site: http://www.isac-net.org/media/standards/miflowcyt/latest.pdf
- Latest version from this flowcyt.sourceforge.net web site: http://flowcyt.sourceforge.net/miflowcyt/latest.pdf
| Last update: February 26th, 2008 |